News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TopoTarget A/S Release: Final Data From BELIEF Study for American Society of Clinical Oncology 2013 Confirms Objective Response Rate of 26%



5/16/2013 9:55:16 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Topotarget announces that an abstract containing positive final data from the registrational BELIEF study with belinostat in peripheral T-cell lymphoma (PTCL) has been released for presentation on ASCO (American Society of Clinical Oncology) 2013 on May 31-June 4, 2013. The abstract concludes that the BELIEF study has an objective response rate (ORR) of 26%.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES